Efavirenz-Based Therapy for Acute HIV Infection

Once-daily tenofovir/FTC/efavirenz was generally effective in treating patients with acute HIV infection.

When prescribing antiretroviral therapy (ART) for acute HIV infection, clinicians tend to recommend protease inhibitors (PIs) rather than nonnucleoside reverse transcriptase inhibitors (NNRTIs) because of concerns about transmitted NNRTI resistance. However, new research suggests that efavirenz-based therapy might be a reasonable option for acute HIV infection.

Investigators conducted a single-arm, manufacturer-supported study of once-daily tenofovir/FTC/efavirenz (Atripla) among 61 patients with acute HIV infection (defined as a negative or indeterminate enzyme immunoassay or a negative HIV RNA assay within 45 days of enrollment, followed by a positive HIV nucleic acid test or enzyme immunoassay). The primary endpoint was a viral load <200 …

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Efavirenz-Based Therapy for Acute HIV Infection

Topics

Reviewing Author